Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgia

Arthritis Research and Therapy

Volumn 15, Issue 6, 2013, Pages

  Spaeth, Michael ^a,f   Alegre, Cayetano ^b   Perrot, Serge ^c   Wang, Youyu G ^d   Guinta, Diane R ^d   Alvarez Horine, Sarah ^d   Russell, Irwin J ^e  

^a Rheumatologische Schwerpunktpraxis   (Germany)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

^c HÔTEL DIEU   (France)

^d JAZZ PHARMACEUTICALS   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f Leitender Arzt Rheumatologie ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

OXYBATE SODIUM; PLACEBO; CENTRAL DEPRESSANT AGENT;

ABDOMINAL PAIN; ACUTE CHOLECYSTITIS; ADJUSTMENT DISORDER; ADULT; AGED; ANOREXIA; ANXIETY; ARTERIOSCLEROSIS; ARTICLE; BODY MASS; BODY WEIGHT; BRAIN TOXICITY; BREAST CANCER; BREATHING RATE; CARCINOMA IN SITU; CHOLELITHIASIS; CHRONIC CHOLECYSTITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; CONSCIOUSNESS LEVEL; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DECREASED APPETITE; DEPRESSION; DIARRHEA; DISEASE DURATION; DIVERTICULITIS; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENDOMETRIOSIS; EVENING DOSAGE; FAINTNESS; FALLING; FEMALE; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; GASTROINTESTINAL MOTILITY DISORDER; HANGOVER; HEART ATRIUM FIBRILLATION; HUMAN; HYPERSOMNIA; INCREASED APPETITE; INFLUENZA; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; OVARY CYST; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATION DEPRESSION; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SEDATION; SIDE EFFECT; SINUSITIS; SLEEP DISORDERED BREATHING; SLEEP WALKING; SOMATOFORM DISORDER; STAPHYLOCOCCAL BACTEREMIA; THORAX PAIN; TRAFFIC ACCIDENT; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERTEBRAL CANAL STENOSIS; VIRAL GASTROENTERITIS; VISUAL ANALOG SCALE; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; MIDDLE AGED; TIME;

ADULT; AGED; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DOUBLE-BLIND METHOD; FEMALE; FIBROMYALGIA; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; SODIUM OXYBATE; TIME;

EID: 84887190762     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4375     Document Type: Article

References (55)

1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russell IJ, Sheon RP. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33:160-172.
2. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010, 62:600-610.
3. Jain AK, Carruthers BM, van de Sande MI, Barron SR, Donaldson CCS, Dunne JV, Gingrich E, Heffez DS, Leung FY-K, Malone DG, Romano TJ, Russell IJ, Saul D, Seibel DG. Fibromyalgia syndrome: Canadian clinical working case definition, diagnostic, and treatment protocols-a consensus document. J Musculoskelet Pain 2003, 11:3-107.
4. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995, 38:19-28.
5. Wolfe F, Anderson J, Harkness D, Bennett RM, Caro XJ, Goldenberg DL, Russell IJ, Yunus MB. Health status and disease severity in fibromyalgia. Results of a six-center longitudinal study. Arthritis Rheum 1997, 40:1571-1579.
6. Alegre De Miquel C, Sellas Fernández A. Fibromyalgia: feeling and pain. Med Clin (Barc) 2008, 131:503-504.
7. Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM, Martin SA, Morea J, Simon L, Strand CV, Williams DA, OMERACT Fibromyalgia Working Group Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol 2009, 36:2318-2329. OMERACT Fibromyalgia Working Group.
8. Choy EH, Mease PJ. Key symptom domains to be assessed in fibromyalgia (outcome measures in rheumatoid arthritis clinical trials). Rheum Dis Clin North Am 2009, 35:329-337.
9. Perrot S, Bouhassira D, Fermanian J, Cercle d'Etude de la Douleur en Rhumatologie Development and validation of the Fibromyalgia Rapid Screening Tool (FiRST). Pain 2010, 150:250-256. Cercle d'Etude de la Douleur en Rhumatologie.
10. Cymbalta® (duloxetine hydrochloride) delayed-release capsules prescribing information Eli Lilly and Company, Indianapolis, IN 2011, http://pi.lilly.com/us/cymbalta-pi.pdf, Cymbalta® (duloxetine hydrochloride) delayed-release capsules prescribing information.
11. Savella® (milnacipran hydrochloride) prescribing information Forest Pharmaceuticals, St. Louis, MO 2009, http://www.frx.com/pi/Savella_pi.pdf, Savella® (milnacipran hydrochloride) prescribing information.
12. Lyrica® (pregabalin) capsules prescribing information Pfizer, Inc., New York, NY 2011, http://labeling.pfizer.com/ShowLabeling.aspx?id=561, Lyrica® (pregabalin) capsules prescribing information.
13. Arnold LM, Emir B, Murphy TK, Zeiher BG, Pauer L, Scott G, Petersel D. Safety profile and tolerability of up to 1 year of pregabalin treatment in 3 open-label extension studies in patients with fibromyalgia. Clin Ther 2012, 34:1092-1102.
14. Branco JC, Cherin P, Montagne A, Bouroubi A. Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study. J Rheumatol 2011, 38:1403-1412.
15. Chappell AS, Littlejohn G, Kajdasz DK, Scheinberg M, D'Souza DN, Moldofsky H. A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. Clin J Pain 2009, 25:365-375.
16. Mease PJ, Russell IJ, Kajdasz DK, Wiltse CG, Detke MJ, Wohlreich MM, Walker DJ, Chappell AS. Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Semin Arthritis Rheum 2010, 39:454-464.
17. Goldenberg DL, Clauw DJ, Palmer RH, Mease P, Chen W, Gendreau RM. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Med 2010, 11:180-194.
18. Hauser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome-a systematic review. Eur J Pain 2010, 14:5-10.
19. Hauser W, Petzke F, Uceyler N, Sommer C. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology (Oxford) 2011, 50:532-543.
20. Nishishinya B, Urrutia G, Walitt B, Rodriguez A, Bonfill X, Alegre C, Darko G. Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy. Rheumatology (Oxford) 2008, 47:1741-1746.
21. Hauser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain 2007, 11:505-521.
22. Hauser W, Urrutia G, Tort S, Uceyler N, Walitt B. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database Syst Rev 2013, 1:CD010292.
23. Walitt B, Fitzcharles MA, Hassett AL, Katz RS, Hauser W, Wolfe F. The longitudinal outcome of fibromyalgia: a study of 1555 patients. J Rheumatol 2011, 38:2238-2246.
24. Xyrem® (sodium oxybate) oral solution US prescribing information Jazz Pharmaceuticals, Inc., Palo Alto, CA 2005, http://www.xyrem.com/images/XYREM_PI.pdf, Xyrem® (sodium oxybate) oral solution US prescribing information.
25. Xyrem® (sodium oxybate) 500 mg/mL oral solution European Union Summary of Product Characteristics 2005, http://ec.europa.eu/health/documents/community-register/2005/2005101310028/anx_10028_en.pdf, Xyrem® (sodium oxybate) 500 mg/mL oral solution.
26. Xyrem® (sodium oxybate) oral solution Canadian Product Monograph, Valeant Canada Ltd 2009, http://webprod5.hc-sc.gc.ca/dpd-bdpp/dispatch-repartition.do?lang=eng, Xyrem® (sodium oxybate) oral solution.
27. Black J, Pardi D, Hornfeldt CS, Inhaber N. The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. Sleep Med 2009, 10:829-835.
28. Black J, Pardi D, Hornfeldt CS, Inhaber N. The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy. J Clin Sleep Med 2010, 6:596-602.
29. Moldofsky H, Inhaber NH, Guinta DR, Alvarez-Horine SB. Effects of sodium oxybate on sleep physiology and sleep/wake-related symptoms in patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study. J Rheumatol 2010, 37:2156-2166.
30. Russell IJ, Perkins AT, Michalek JE, Oxybate SXB-26 Fibromyalgia Syndrome Study Group Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum 2009, 60:299-309. Oxybate SXB-26 Fibromyalgia Syndrome Study Group.
31. Choy E, Alegre C, Sarzi-Puttini P, van Seventer R, Wang YG, Guinta D, Lai C, Bennett R, Sodium Oxybate in Fibromyalgia 06-009 Study Group The effects of sodium oxybate on sleep disturbance, fatigue, and functioning in fibromyalgia: results from a phase 3, randomized, double-blind, placebo-controlled international trial [abstract]. Ann Rheum Dis 2010, 69:449. Sodium Oxybate in Fibromyalgia 06-009 Study Group.
32. Russell IJ, Holman AJ, Swick TJ, Alvarez-Horine S, Wang YG, Guinta D, Sodium Oxybate 06-008 FM Study Group Sodium oxybate reduces pain, fatigue, and sleep disturbance and improves functionality in fibromyalgia: results from a 14-week, randomized, double-blind, placebo-controlled study. Pain 2011, 152:1007-1017. Sodium Oxybate 06-008 FM Study Group.
33. Spaeth M, Bennett RM, Benson BA, Wang YG, Lai C, Choy EH. Sodium oxybate therapy provides multidimensional improvement in fibromyalgia: results of an international phase 3 trial. Ann Rheum Dis 2012, 71:935-942.
34. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, et al. IMMPACT: Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005, 113:9-19.
35. Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB. Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol 2009, 36:1304-1311.
36. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59:22-33.
37. Beck A, Steer RA, Brown GK. BDI-II: Beck Depression Inventory Manual - (2nd Edition) 1996, San Antonio: The Psychological Corporation, Harcourt Brace & Company.
38. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991, 18:728-733.
39. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare publication (ADM 76-338) 1976, Rockville, MD: National Institute of Mental Health.
40. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483.
41. Weaver TE, Laizner AM, Evans LK, Maislin G, Chugh DK, Lyon K, Smith PL, Schwartz AR, Redline S, Pack AI, Dinges DF. An instrument to measure functional status outcomes for disorders of excessive sleepiness. Sleep 1997, 20:835-843.
42. Carter LP, Pardi D, Gorsline J, Griffiths RR. Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse. Drug Alcohol Depend 2009, 104:1-10.
43. Burckhardt CS, O'Reilly CA, Wiens AN, Clark SR, Campbell SM, Bennett RM. Assessing depression in fibromyalgia patients. Arthritis Care Res 1994, 7:35-39.
44. Kassam A, Patten SB. Major depression, fibromyalgia and labour force participation: a population-based cross-sectional study. BMC Musculoskelet Disord 2006, 7:4.
45. Dreyer L, Kendall S, Danneskiold-Samsøe B, Bartels EM, Bliddal H. Mortality in a cohort of Danish patients with fibromyalgia: increased frequency of suicide. Arthritis Rheum 2010, 62:3101-3108.
46. Calandre EP, Vilchez JS, Molina-Barea R, Tovar MI, Garcia-Leiva JM, Hidalgo J, Rodriguez-Lopez CM, Rico-Villademoros F. Suicide attempts and risk of suicide in patients with fibromyalgia: a survey in Spanish patients. Rheumatology (Oxford) 2011, 50:1889-1893.
47. Wolfe F, Hassett AL, Walitt B, Michaud K. Mortality in fibromyalgia: a study of 8,186 patients over thirty-five years. Arthritis Care Res (Hoboken) 2011, 63:94-101.
48. Husain AM, Ristanovic RK, Bogan RK. Weight loss in narcolepsy patients treated with sodium oxybate. Sleep Med 2009, 10:661-663.
49. BMI Classification [http://apps.who.int/bmi/index.jsp?introPage=intro_3.html].
50. Farrar JT, Pritchett YL, Robinson M, Prakash A, Chappell A. The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disorders. J Pain 2010, 11:109-118.
51. Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010, 62:2745-2756.
52. Branco JC, Zachrisson O, Perrot S, Mainguy Y, Multinational Coordinator Study Group A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. J Rheumatol 2010, 37:851-859. Multinational Coordinator Study Group.
53. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008, 30:1988-2004.
54. Geisser ME, Palmer RH, Gendreau RM, Wang Y, Clauw DJ. A pooled analysis of two randomized, double-blind, placebo-controlled trials of milnacipran monotherapy in the treatment of fibromyalgia. Pain Pract 2011, 11:120-131.
55. Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, Palmer RH. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol 2009, 36:398-409.